Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Supports Emergency Screening of Avian Influenza (H7N9) Virus

Published: Monday, April 29, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Company's instruments FDA-cleared under Emergency Use Authorization declaration.

Life Technologies Corporation announced that its Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument is the sole platform cleared for use under the Centers for Disease Control and Prevention (CDC) protocol created for emergency screenings of patients suspected of harbouring the Avian influenza (H7N9) virus, which to date has led to 23 deaths in China and Taiwan.

Cleared under the U.S. Food and Drug Administration's (FDA) Emergency Use Authorization (EUA), the 7500 Fast Dx Real-Time PCR instrument, in addition to Life's SuperScript III One-Step qRT-PCR reagent kit, is intended to be used with the CDC's human influenza virus assay to quickly monitor the spread of the pathogen and thwart a potential pandemic. To support this global need, Life Technologies is increasing production of its reagents and shipping them to labs around the world.

Life Technologies has a strong history of working with the CDC, the World Health Organization (WHO) and public health labs to combat virus outbreaks:

•    2009 — Life Technologies formed a special 24-hour-a-day task force to respond to global requests for assistance with the H1N1 outbreak.  
•    2011 — Life Technologies developed a custom assay to accurately detect the E. coli bacterium that spread through Europe.  The assay was developed after company researchers, using samples supplied by scientists at University Hospital Munster, completed the DNA sequencing and analysis work on the deadly E. coli strain using the Ion PGM™ Sequencer.     
•    2012 — Life Technologies established the Global Influenza Network, a partnership of scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes who collaborate in an effort to increase the speed and efficiency of influenza monitoring and vaccine development.  
•    Today — Life Technologies' Ion PGM™ Sequencer is being used to characterize the genetic sequence of the virus and to determine if it can be transmitted from human to human.

"We have learned through our past experiences that a strong surveillance program is crucial in times like these," said Dan Didier, Public Health Director for Life Technologies.  "We are working continually with our partners around the globe on improving our capabilities, particularly when it comes to developing rapid detection kits."

Cases of the H7N9 virus have been reported out of China and Taiwan only.  First cases of the human virus were confirmed in March with more than 100 cases.

SuperScript III One-Step qRT-PCR kit is for research use only; not intended for diagnostic purposes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Screening Technology Receives Emergency Use Authorization
Life Technologies supports global effort to help accelerate emergency screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Wednesday, June 26, 2013
JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test
Genetic test identifies patients at high risk for mortality in the earliest stage of lung cancer. Study suggests test could maximize the benefits of early screening if used in combination with computed tomography.
Thursday, November 08, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!